{"id":"NCT03525613","sponsor":"Apellis Pharmaceuticals, Inc.","briefTitle":"A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-31","primaryCompletion":"2021-06-28","completion":"2022-06-28","firstPosted":"2018-05-15","resultsPosted":"2023-07-06","lastUpdate":"2023-07-06"},"enrollment":637,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Geographic Atrophy"],"interventions":[{"type":"DRUG","name":"APL-2","otherNames":["Pegcetacoplan"]},{"type":"DRUG","name":"APL-2","otherNames":["Pegcetacoplan"]},{"type":"OTHER","name":"Sham Procedure","otherNames":[]},{"type":"OTHER","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"APL-2 15mg 0.1 mL Monthly for 24 months","type":"EXPERIMENTAL"},{"label":"APL-2 15mg 0.1 mL EOM for 24 months","type":"EXPERIMENTAL"},{"label":"Sham Procedure Monthly for 24 months","type":"EXPERIMENTAL"},{"label":"Sham Procedure Every Other Month for 24 months","type":"EXPERIMENTAL"}],"summary":"This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.","primaryOutcome":{"measure":"Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12","timeFrame":"Baseline (screening) and Month 12","effectByArm":[{"arm":"Pegcetacoplan Monthly","deltaMin":1.5579,"sd":0.0835},{"arm":"Pegcetacoplan EOM","deltaMin":1.6512,"sd":0.08118},{"arm":"Sham Pooled","deltaMin":1.9692,"sd":0.08218}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0004"},{"comp":"OG001 vs OG002","p":"0.0055"}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":112,"countries":["United States","Australia","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Netherlands","New Zealand","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40388106","38722644","37865470","37314061"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":213},"commonTop":["Visual acuity reduced","Dry eye","Urinary tract infection","Neovascular age-related macular degeneration","Conjunctival haemorrhage"]}}